KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 65 filers reported holding KALVISTA PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $999,536 | +12.0% | 103,794 | +4.7% | 0.00% | +50.0% |
| Q2 2023 | $892,458 | +108.9% | 99,162 | +82.4% | 0.00% | +100.0% |
| Q1 2023 | $427,309 | +263.0% | 54,365 | +212.2% | 0.00% | – |
| Q4 2022 | $117,732 | -68.1% | 17,416 | -53.5% | 0.00% | -100.0% |
| Q2 2022 | $369,000 | -71.4% | 37,453 | -61.6% | 0.00% | -66.7% |
| Q4 2021 | $1,291,000 | -39.7% | 97,592 | -20.4% | 0.00% | -40.0% |
| Q3 2021 | $2,140,000 | +57.0% | 122,643 | +115.6% | 0.01% | +66.7% |
| Q2 2021 | $1,363,000 | -34.2% | 56,878 | -29.5% | 0.00% | -40.0% |
| Q1 2021 | $2,072,000 | +284.4% | 80,673 | +184.1% | 0.01% | +150.0% |
| Q4 2020 | $539,000 | +63.3% | 28,396 | +4.2% | 0.00% | 0.0% |
| Q2 2020 | $330,000 | +8.9% | 27,262 | +99.1% | 0.00% | +100.0% |
| Q2 2019 | $303,000 | +7.4% | 13,696 | +7.5% | 0.00% | 0.0% |
| Q3 2018 | $282,000 | – | 12,740 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Prosight Management, LP | 589,270 | $8,686,000 | 5.61% |
| GREAT POINT PARTNERS LLC | 874,197 | $12,886,000 | 3.11% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 383,233 | $10,805,000 | 2.44% |
| Frazier Life Sciences Management, L.P. | 1,572,192 | $23,174,000 | 1.98% |
| TANG CAPITAL MANAGEMENT LLC | 648,269 | $9,555,000 | 1.91% |
| Deep Track Capital, LP | 1,729,757 | $25,497,000 | 1.64% |
| Vivo Capital, LLC | 1,533,559 | $22,605,000 | 1.56% |
| Monashee Investment Management LLC | 264,111 | $3,893,000 | 1.13% |
| COMMODORE CAPITAL LP | 312,553 | $4,607,000 | 1.03% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,746,300 | $25,740,000 | 0.79% |